Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,000 shares of the stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $38.11, for a total transaction of $76,220.00. Following the completion of the sale, the executive vice president now directly owns 140,255 shares of the company's stock, valued at $5,345,118.05. This represents a 1.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Fady Ibraham Malik also recently made the following trade(s):
- On Tuesday, February 18th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The stock was sold at an average price of $45.98, for a total transaction of $91,960.00.
- On Tuesday, February 4th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $48.06, for a total transaction of $96,120.00.
Cytokinetics Stock Down 0.3 %
Shares of NASDAQ:CYTK opened at $37.81 on Wednesday. The company has a market cap of $4.51 billion, a price-to-earnings ratio of -7.03 and a beta of 0.94. Cytokinetics, Incorporated has a 12 month low of $32.74 and a 12 month high of $68.76. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. The company has a 50-day moving average price of $42.47 and a 200 day moving average price of $47.46.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.03. The company had revenue of $16.93 million during the quarter, compared to the consensus estimate of $14.26 million. As a group, equities research analysts predict that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the company. Jones Financial Companies Lllp lifted its holdings in shares of Cytokinetics by 189.8% in the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 374 shares during the last quarter. Centricity Wealth Management LLC purchased a new stake in Cytokinetics in the 4th quarter worth about $29,000. Fifth Third Bancorp lifted its stake in Cytokinetics by 42.2% in the first quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 291 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Cytokinetics by 500.5% during the first quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company's stock valued at $44,000 after buying an additional 916 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of Cytokinetics by 281.0% during the first quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 826 shares during the last quarter.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on CYTK shares. Morgan Stanley set a $67.00 price target on Cytokinetics in a report on Friday, March 7th. Citigroup started coverage on Cytokinetics in a research note on Friday, February 7th. They set a "buy" rating and a $86.00 target price on the stock. HC Wainwright restated a "buy" rating and issued a $120.00 price target on shares of Cytokinetics in a research note on Monday. Stifel Nicolaus started coverage on shares of Cytokinetics in a research report on Wednesday, January 22nd. They set a "buy" rating and a $80.00 price objective on the stock. Finally, JMP Securities restated a "market outperform" rating and set a $78.00 target price on shares of Cytokinetics in a research report on Thursday, April 10th. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $81.63.
Get Our Latest Stock Report on CYTK
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
